medication_name stringlengths 6 170 | section_title stringclasses 42 values | text stringlengths 0 47.1k |
|---|---|---|
Gefitinib 250 mg Film-Coated Tablets | Clinical particulars - Posology and method of administration | Posology and method of administration
Treatment with Gefitinib should be initiated and supervised by a physician experienced in the use of anticancer therapies.
Posology
The recommended posology of Gefitinib is one 250 mg tablet once a day. If a dose is missed, it should be taken as soon as the patient remembers. If it is less than 12 hours to the next dose, the patient should not take the missed dose. Patients should not take a double dose (two doses at the same time) to make up for a forgotten dose.
Paediatric population
The safety and efficacy of Gefitinib in children and adolescents aged less than 18 years have not been established. There is no relevant use of gefitinib in the paediatric population in the indication of NSCLC.
Hepatic impairment
Patients with moderate to severe hepatic impairment (Child-Pugh B or C) due to cirrhosis have increased plasma concentrations of gefitinib. These patients should be closely monitored for adverse events. Plasma concentrations were not increased in patients with elevated aspartate transaminase (AST), alkaline phosphatase or bilirubin due to liver metastases (see section 5.2).
Renal impairment
No dose adjustment is required in patients with impaired renal function at creatinine clearance > 20 ml/min. Only limited data are available in patients with creatinine clearance ≤ 20 ml/min and caution is advised in these patients (see section 5.2).
Elderly
No dose adjustment is required on the basis of patient age (see section 5.2).
CYP2D6 poor metabolisers
No specific dose adjustment is recommended in patients with known CYP2D6 poor metaboliser genotype, but these patients should be closely monitored for adverse events (see section 5.2).
Dose adjustment due to toxicity
Patients with poorly tolerated diarrhoea or skin adverse reactions may be successfully managed by providing a brief (up to 14 days) therapy interruption followed by reinstatement of the 250 mg dose (see section 4.8). For patients unable to tolerate treatment after a therapy interruption, gefitinib should be discontinued and an alternative treatment should be considered.
Method of administration
The tablet may be taken orally with or without food, at about the same time each day. The tablet can be swallowed whole with some water or if dosing of whole tablets is not possible, tablets may be administered as a dispersion in water (non-carbonated). No other liquids should be used. Without crushing it, the tablet should be dropped in half a glass of drinking water. The glass should be swirled occasionally, until the tablet is dispersed (this may take up to 20 minutes). The dispersion should be drunk immediately after dispersion is complete (i.e. within 60 minutes). The glass should be rinsed with half a glass of water, which should also be drunk. The dispersion can also be administered through a naso-gastric or gastrostomy tube.
4.3 |
Gefitinib 250 mg Film-Coated Tablets | Clinical particulars - Contraindications | Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Breast-feeding (see section 4.6).
4.4 |
Gefitinib 250 mg Film-Coated Tablets | Clinical particulars - Special warnings and precautions for use | Special warnings and precautions for use
When considering the use of gefitinib as a treatment for locally advanced or metastatic NSCLC, it is important that EGFR mutation assessment of the tumour tissue is attempted for all patients. If a tumour sample is not evaluable, then circulating tumour DNA (ctDNA) obtained from a blood (plasma) sample may be used.
Only robust, reliable and sensitive test(s) with demonstrated utility for the determination of EGFR mutation status of tumours or ctDNA should be used to avoid false negative or false positive determinations (see section 5.1).
Interstitial lung disease (ILD)
Interstitial lung disease (ILD), which may be acute in onset, has been observed in 1.3 % of patients receiving gefitinib, and some cases have been fatal (see section 4.8). If patients experience worsening of respiratory symptoms such as dyspnoea, cough and fever, gefitinib should be interrupted and the patient should be promptly investigated. If ILD is confirmed, gefitinib should be discontinued and the patient treated appropriately.
In a Japanese pharmacoepidemiological case control study in 3 159 patients with NSCLC receiving gefitinib or chemotherapy who were followed up for 12 weeks, the following risk factors for developing ILD (irrespective of whether the patient received gefitinib or chemotherapy) were identified: smoking, poor performance status (PS≥ 2), CT scan evidence of reduced normal lung (≤ 50 %), recent diagnosis of NSCLC (< 6 months), pre-existing ILD, older age (≥ 55 years old) and concurrent cardiac disease. An increased risk of ILD on gefitinib relative to chemotherapy was seen predominantly during the first 4 weeks of treatment (adjusted OR 3.8; 95 % CI 1.9 to 7.7); thereafter the relative risk was lower (adjusted OR 2.5; 95 % CI 1.1 to 5.8). Risk of mortality among patients who developed ILD on gefitinib or chemotherapy was higher in patients with the following risk factors: smoking, CT scan evidence of reduced normal lung (≤ 50 %), pre-existing ILD, older age (≥ 65 years old), and extensive areas adherent to pleura (≥ 50 %).
Hepatotoxicity and liver impairment
Liver function test abnormalities (including increases in alanine aminotransferase, aspartate aminotransferase, bilirubin) have been observed, uncommonly presenting as hepatitis (see section 4.8). There have been isolated reports of hepatic failure which in some cases led to fatal outcomes.
Therefore, periodic liver function testing is recommended. Gefitinib should be used cautiously in the presence of mild to moderate changes in liver function. Discontinuation should be considered if changes are severe.
Impaired liver function due to cirrhosis has been shown to lead to increased plasma concentrations of gefitinib (see section 5.2).
Interactions with other medicinal products
CYP3A4 inducers may increase metabolism of gefitinib and decrease gefitinib plasma concentrations. Therefore, concomitant administration of CYP3A4 inducers (e.g. phenytoin, carbamazepine, rifampicin, barbiturates or herbal preparations containing St John's wort/Hypericum perforatum) may reduce efficacy of the treatment and should be avoided (see section 4.5).
In individual patients with CYP2D6 poor metaboliser genotype, treatment with a potent CYP3A4 inhibitor might lead to increased plasma levels of gefitinib. At initiation of treatment with a CYP3A4 inhibitor, patients should be closely monitored for gefitinib adverse reactions (see section 4.5).
International normalised ratio (INR) elevations and/or bleeding events have been reported in some patients taking warfarin together with gefitinib (see section 4.5). Patients taking warfarin and gefitinib concomitantly should be monitored regularly for changes in prothrombin time (PT) or INR.
Medicinal products that cause significant sustained elevation in gastric pH, such as proton-pump inhibitors and h2-antagonists may reduce bioavailability and plasma concentrations of gefitinib and, therefore, may reduce efficacy. Antacids if taken regularly close in time to administration of gefitinib may have a similar effect (see sections 4.5 and 5.2).
Data from phase II clinical trials, where gefitinib and vinorelbine have been used concomitantly, indicate that gefitinib may exacerbate the neutropenic effect of vinorelbine.
Lactose
Gefitinib contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Sodium
This medicinal product contains less than 1 mmol sodium (23 mg) per film-coated tablet, that is to say essentially 'sodium-free'.
Further precautions for use
Patients should be advised to seek medical advice immediately if they experience severe or persistent diarrhoea, nausea, vomiting or anorexia as these may indirectly lead to dehydration. These symptoms should be managed as clinically indicated (see section 4.8).
Patients presenting with signs and symptoms suggestive of keratitis such as acute or worsening: eye inflammation, lacrimation, light sensitivity, blurred vision, eye pain and/or red eye should be referred promptly to an ophthalmology specialist.
If a diagnosis of ulcerative keratitis is confirmed, treatment with gefitinib should be interrupted, and if symptoms do not resolve, or if symptoms recur on reintroduction of gefitinib, permanent discontinuation should be considered.
In a phase I/II trial studying the use of gefitinib and radiation in paediatric patients, with newly diagnosed brain stem glioma or incompletely resected supratentorial malignant glioma, 4 cases (1 fatal) of Central Nervous System (CNS) haemorrhages were reported from 45 patients enrolled. A further case of CNS haemorrhage has been reported in a child with an ependymoma from a trial with gefitinib alone. An increased risk of cerebral haemorrhage in adult patients with NSCLC receiving gefitinib has not been established.
Gastrointestinal perforation has been reported in patients taking gefitinib. In most cases this is associated with other known risk factors, including concomitant medications such as steroids or NSAIDS, underlying history of GI ulceration, age, smoking or bowel metastases at sites of perforation.
4.5 |
Gefitinib 250 mg Film-Coated Tablets | Clinical particulars - Interaction with other medicinal products and other forms of interaction | Interaction with other medicinal products and other forms of interaction
The metabolism of gefitinib is via the cytochrome P450 isoenzyme CYP3A4 (predominantly) and via CYP2D6.
Active substances that may increase gefitinib plasma concentrations
In vitro studies have shown that gefitinib is a substrate of p-glycoprotein (Pgp). Available data do not suggest any clinical consequences to this in vitro finding.
Substances that inhibit CYP3A4 may decrease the clearance of gefitinib. Concomitant administration with potent inhibitors of CYP3A4 activity (e.g. ketoconazole, posaconazole, voriconazole, protease inhibitors, clarithromycin, telithromycin) may increase gefitinib plasma concentrations. The increase may be clinically relevant since adverse reactions are related to dose and exposure. The increase might be higher in individual patients with CYP2D6 poor metaboliser genotype. Pre-treatment with itraconazole (a potent CYP3A4 inhibitor) resulted in an 80 % increase in the mean AUC of gefitinib in healthy volunteers. In situations of concomitant treatment with potent inhibitors of CYP3A4 the patient should be closely monitored for gefitinib adverse reactions.
There are no data on concomitant treatment with an inhibitor of CYP2D6 but potent inhibitors of this enzyme might cause increased plasma concentrations of gefitinib in CYP2D6 extensive metabolisers by about 2-fold (see section 5.2). If concomitant treatment with a potent CYP2D6 inhibitor is initiated, the patient should be closely monitored for adverse reactions.
Active substances that may reduce gefitinib plasma concentrations
Substances that are inducers of CYP3A4 activity may increase metabolism and decrease gefitinib plasma concentrations and thereby reduce the efficacy of gefitinib. Concomitant medicinal products that induce CYP3A4 (e.g. phenytoin, carbamazepine, rifampicin, barbiturates or St John's wort, Hypericum perforatum) should be avoided. Pre-treatment with rifampicin (a potent CYP3A4 inducer) in healthy volunteers reduced mean gefitinib AUC by 83 % (see section 4.4).
Substances that cause significant sustained elevation in gastric pH may reduce gefitinib plasma concentrations and thereby reduce the efficacy of gefitinib. High doses of short-acting antacids may have a similar effect if taken regularly close in time to administration of gefitinib. Concomitant administration of gefitinib with ranitidine at a dose that caused sustained elevations in gastric pH ≥5 resulted in a reduced mean gefitinib AUC by 47 % in healthy volunteers (see section 4.4 and 5.2).
Active substances that may have their plasma concentrations altered by gefitinib
In vitro studies have shown that gefitinib has limited potential to inhibit CYP2D6. In a clinical trial in patients, gefitinib was co-administered with metoprolol (a CYP2D6 substrate). This resulted in a 35 % increase in exposure to metoprolol. Such an increase might potentially be relevant for CYP2D6 substrates with narrow therapeutic index. When the use of CYP2D6 substrates are considered in combination with gefitinib, a dose modification of the CYP2D6 substrate should be considered especially for products with a narrow therapeutic window.
Gefitinib inhibits the transporter protein BCRP in vitro, but the clinical relevance of this finding is unknown.
Other potential interactions
INR elevations and/or bleeding events have been reported in some patients concomitantly taking warfarin (see section 4.4).
4.6 |
Gefitinib 250 mg Film-Coated Tablets | Clinical particulars - Fertility, pregnancy and lactation | Fertility, pregnancy and lactation
Women of childbearing potential
Women of childbearing potential must be advised not to get pregnant during therapy.
Pregnancy
There are no data from the use of gefitinib in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown. Gefitinib should not be used during pregnancy unless clearly necessary.
Breast-feeding
It is not known whether gefitinib is secreted in human milk. Gefitinib and metabolites of gefitinib accumulated in milk of lactating rats (see section 5.3). Gefitinib is contraindicated during breast-feeding and therefore breast-feeding must be discontinued while receiving gefitinib therapy (see section 4.3).
4.7 |
Gefitinib 250 mg Film-Coated Tablets | Clinical particulars - Effects on ability to drive and use machines | Effects on ability to drive and use machines
During treatment with gefitinib, asthenia has been reported. Therefore, patients who experience this symptom should be cautious when driving or using machines.
4.8 |
Gefitinib 250 mg Film-Coated Tablets | Clinical particulars - Undesirable effects | Undesirable effects
Summary of the safety profile
In the pooled dataset from the ISEL, INTEREST and IPASS phase III clinical trials (2462 gefitinib-treated patients), the most frequently reported adverse drug reactions (ADRs), occurring in more than 20 % of the patients, are diarrhoea and skin reactions (including rash, acne, dry skin and pruritus). ADRs usually occur within the first month of therapy and are generally reversible. Approximately 8 % of patients had a severe ADR (common toxicity criteria, (CTC) grade 3 or 4).
Approximately 3 % of patients stopped therapy due to an ADR.
Interstitial lung disease (ILD) has occurred in 1.3 % of patients, often severe (CTC grade 3-4). Cases with fatal outcomes have been reported.
Tabulated list of adverse reactions
The safety profile presented in Table 1 is based on the gefitinib clinical development programme and postmarketed experience. Adverse reactions have been assigned to the frequency categories in Table 1 where possible based on the incidence of comparable adverse event reports in a pooled dataset from the ISEL, INTEREST and IPASS phase III clinical trials (2462 gefitinib-treated patients).
Frequencies of occurrence of undesirable effects are defined as: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1 000 to < 1/100); rare (≥ 1/10 000 to < 1/1,000); very rare (< 1/10 000), not known (cannot be estimated from the available data).
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
Table 1 Adverse reactions
Adverse reactions by system organ class and frequency
Metabolism and nutrition disorders
Very common
Anorexia mild or moderate (CTC grade 1 or 2).
Eye disorders
Common
Conjunctivitis, blepharitis, and dry eye*, mainly mild (CTC grade 1).
Uncommon
Corneal erosion, reversible and sometimes in association with aberrant eyelash growth.
Keratitis (0.12 %)
Vascular disorders
Common
Haemorrhage, such as epistaxis and haematuria.
Respiratory, thoracic and mediastinal disorders
Common
Interstitial lung disease (1.3 %), often severe (CTC grade 3-4). Cases with fatal outcomes have been reported.
Gastrointestinal disorders
Very common
Diarrhoea, mainly mild or moderate (CTC grade 1 or 2).
Vomiting, mainly mild or moderate (CTC grade 1 or 2).
Nausea, mainly mild (CTC grade 1).
Stomatitis, predominantly mild in nature (CTC grade 1).
Common
Dehydration, secondary to diarrhoea, nausea, vomiting or anorexia.
Dry mouth*, predominantly mild (CTC grade 1).
Uncommon
Pancreatitis; Gastrointestinal perforation.
Hepatobiliary disorders
Very common
Elevations in alanine aminotransferase, mainly mild to moderate.
Common
Elevations in aspartate aminotransferase, mainly mild to moderate.
Elevations in total bilirubin, mainly mild to moderate.
Uncommon
Hepatitis**.
Skin and subcutaneous tissue disorders
Very Common
Skin reactions, mainly a mild or moderate (CTC grade 1 or 2) pustular rash, sometimes itchy with dry skin, including skin fissures, on an erythematous base.
Common
Nail disorder
Alopecia
Allergic reactions (1.1 %), including angioedema and urticaria .
Uncommon
Palmar-plantar erythrodysaesthesia syndrome.
Rare
Bullous conditions including Toxic epidermal necrolysis, Stevens Johnson syndrome and erythema multiforme.
Cutaneous vasculitis.
Renal and urinary disorders
Common
Asymptomatic laboratory elevations in blood creatinine.
Proteinuria.
Cystitis.
Rare
Haemorrhagic cystitis.
General disorders and administration site conditions
Very Common
Asthenia, predominantly mild (CTC grade 1).
Common
Pyrexia.
The frequency of adverse drug reactions relating to abnormal laboratory values is based on patients with a change from baseline of 2 or more CTC grades in the relevant laboratory parameters.
* This adverse reaction can occur in association with other dry conditions (mainly skin reactions) seen with gefitinib.
** This includes isolated reports of hepatic failure which in some cases led to fatal outcomes.
Interstitial lung disease (ILD)
In the INTEREST trial, the incidence of ILD type events was 1.4 % (10) patients in the gefitinib group versus 1.1 % (8) patients in the docetaxel group. One ILD-type event was fatal, and this occurred in a patient receiving gefitinib.
In the ISEL trial, the incidence of ILD-type events in the overall population was approximately 1 % in both treatment arms. The majority of ILD-type events reported was from patients of Asian ethnicity and the ILD incidence among patients of Asian ethnicity receiving gefitinib therapy and placebo was approximately 3 % and 4 % respectively. One ILD-type event was fatal, and this occurred in a patient receiving placebo.
In a post-marketing surveillance study in Japan (3350 patients) the reported rate of ILD-type events in patients receiving gefitinib was 5.8 %. The proportion of ILD-type events with a fatal outcome was 38.6 %.
In a phase III open-label clinical trial (IPASS) in 1217 patients comparing gefitinib to carboplatin/paclitaxel doublet chemotherapy as first-line treatment in selected patients with advanced NSCLC in Asia, the incidence of ILD-type events was 2.6 % on the gefitinib treatment arm versus 1.4 % on the carboplatin/paclitaxel treatment arm.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for 'MHRA Yellow Card' in the Google Play or Apple App Store.
4.9 |
Gefitinib 250 mg Film-Coated Tablets | Clinical particulars - Overdose | Overdose
There is no specific treatment in the event of overdose of gefitinib. However, in phase I clinical trials, a limited number of patients were treated with daily doses of up to 1 000 mg. An increase of frequency and severity of some adverse reactions was observed, mainly diarrhoea and skin rash. Adverse reactions associated with overdose should be treated symptomatically; in particular severe diarrhoea should be managed as clinically indicated. In one study a limited number of patients were treated weekly with doses from 1 500 mg to 3 500 mg. In this study gefitinib exposure did not increase with increasing dose, adverse events were mostly mild to moderate in severity, and were consistent with the known safety profile of gefitinib.
5. Pharmacological properties
5.1 |
Gefitinib 250 mg Film-Coated Tablets | Pharmacodynamic properties - Pharmacodynamic properties | Pharmacokinetic properties
Absorption
Following oral administration of gefitinib, absorption is moderately slow and peak plasma concentrations of gefitinib typically occur at 3 to 7 hours after administration. Mean absolute bioavailability is 59 % in cancer patients. Exposure to gefitinib is not significantly altered by food. In a trial in healthy volunteers where gastric pH was maintained above pH 5, gefitinib exposure was reduced by 47 %, likely due to impaired solubility of gefitinib in the stomach (see sections 4.4 and 4.5).
Distribution
Gefitinib has a mean steady-state volume of distribution of 1400 l indicating extensive distribution into tissue. Plasma protein binding is approximately 90 %. Gefitinib binds to serum albumin and alpha 1-acid glycoprotein.
In vitro data indicate that gefitinib is a substrate for the membrane transport protein Pg-p.
Biotransformation
In vitro data indicate that CYP3A4 and CYP2D6 are the major P450 isozyme involved in the oxidative metabolism of gefitinib.
In vitro studies have shown that gefitinib has limited potential to inhibit CYP2D6. Gefitinib shows no enzyme induction effects in animal studies and no significant inhibition (in vitro) of any other cytochrome P450 enzyme.
Gefitinib is extensively metabolised in humans. Five metabolites have been fully identified in excreta and 8 metabolites in plasma. The major metabolite identified was O-desmethyl gefitinib, which is 14-fold less potent than gefitinib at inhibiting EGFR stimulated cell growth and has no inhibitory effect on tumour cell growth in mice. It is therefore considered unlikely that it contributes to the clinical activity of gefitinib.
The formation of O-desmethyl gefitinib has been shown, in vitro, to be via CYP2D6. The role of CYP2D6 in the metabolic clearance of gefitinib has been evaluated in a clinical trial in healthy volunteers genotyped for CYP2D6 status. In poor metabolisers no measurable levels of O-desmethyl gefitinib were produced. The levels of exposure to gefitinib achieved in both the extensive and the poor metaboliser groups were wide and overlapping but the mean exposure to gefitinib was 2-fold higher in the poor metaboliser group. The higher average exposures that could be achieved by individuals with no active CYP2D6 may be clinically relevant since adverse effects are related to dose and exposure.
Elimination
Gefitinib is excreted mainly as metabolites via the faeces, with renal elimination of gefitinib and metabolites accounting for less than 4 % of the administered dose.
Gefitinib total plasma clearance is approximately 500 ml/min and the mean terminal half-life is 41 hours in cancer patients. Administration of gefitinib once daily results in 2- to 8-fold accumulation, with steady-state exposures achieved after 7 to 10 doses. At steady-state, circulating plasma concentrations are typically maintained within a 2- to 3-fold range over the 24-hour dosing interval.
Special populations
From analyses of population pharmacokinetic data in cancer patients, no relationships were identified between predicted steady-state trough concentration and patient age, body weight, gender, ethnicity or creatinine clearance (above 20 ml/min).
Hepatic impairment
In a phase I open-label study of single dose gefitinib 250 mg in patients with mild, moderate or severe hepatic impairment due to cirrhosis (according to Child-Pugh classification), there was an increase in exposure in all groups compared with healthy controls. An average 3.1-fold increase in exposure to gefitinib in patients with moderate and severe hepatic impairment was observed. None of the patients had cancer, all had cirrhosis and some had hepatitis. This increase in exposure may be of clinical relevance since adverse experiences are related to dose and exposure to gefitinib.
Gefitinib has been evaluated in a clinical trial conducted in 41 patients with solid tumours and normal hepatic function, or moderate or severe hepatic impairment (classified according to baseline Common Toxicity Criteria grades for AST, alkaline phosphatase and bilirubin) due to liver metastases. It was shown that following daily administration of 250 mg gefitinib, time to steady-state, total plasma clearance (CmaxSS) and steady-state exposure (AUC24SS) were similar for the groups with normal and moderately impaired hepatic function. Data from 4 patients with severe hepatic impairment due to liver metastases suggested that steady-state exposures in these patients are also similar to those in patients with normal hepatic function.
5.3 |
Gefitinib 250 mg Film-Coated Tablets | Pharmacodynamic properties - Pharmacokinetic properties | Preclinical safety data
Adverse reactions not observed in clinical studies, but seen in animals at exposure levels similar to the clinical exposure levels and with possible relevance to clinical use were as follows:
• Corneal epithelia atrophy and corneal translucencies
• Renal papillary necrosis
• Hepatocellular necrosis and eosinophilic sinusoidal macrophage infiltration
Data from non-clinical (in vitro) studies indicate that gefitinib has the potential to inhibit the cardiac action potential repolarisation process (e.g. QT interval). Clinical experience has not shown a causal association between QT prolongation and gefitinib.
A reduction in female fertility was observed in the rat at a dose of 20 mg/kg/day.
Published studies have shown that genetically modified mice, lacking expression of EGFR, exhibit developmental defects, related to epithelial immaturity in a variety of organs including the skin, gastrointestinal tract and lung. When gefitinib was administered to rats during organogenesis, there were no effects on embryofoetal development at the highest dose (30 mg/kg/day). However, in the rabbit, there were reduced foetal weights at 20 mg/kg/day and above. There were no compound-induced malformations in either species. When administered to the rat throughout gestation and parturition, there was a reduction in pup survival at a dose of 20 mg/kg/day.
Following oral administration of C-14 labelled gefitinib to lactating rats 14 days post partum, concentrations of radioactivity in milk were 11-19 fold higher than in blood.
Gefitinib showed no genotoxic potential.
A 2-year carcinogenicity study in rats resulted in a small but statistically significant increased incidence of hepatocellular adenomas in both male and female rats and mesenteric lymph node haemangiosarcomas in female rats at the highest dose (10 mg/kg/day) only. The hepatocellular adenomas were also seen in a 2-year carcinogenicity study in mice, which demonstrated a small increased incidence of this finding in male mice at the mid dose, and in both male and female mice at the highest dose. The effects reached statistical significance for the female mice, but not for the males. At no-effect levels in both mice and rats there was no margin in clinical exposure. The clinical relevance of these findings is unknown.
The results of an in vitro phototoxicity study demonstrated that gefitinib may have phototoxicity potential.
6. |
Gefitinib 250 mg Film-Coated Tablets | Pharmaceutical particulars - List of excipients | List of excipients
Tablet core
Sodium laurilsulfate
Lactose monohydrate
Cellulose microcrystalline
Povidone
Croscarmellose sodium
Magnesium stearate
Tablet coating
Polyvinyl alcohol
Macrogol
Talc
Iron oxide red (E172)
Iron oxide yellow (E172)
Iron oxide black (E172)
6.2 |
Gefitinib 250 mg Film-Coated Tablets | Pharmaceutical particulars - Incompatibilities | Incompatibilities
Not applicable.
6.3 |
Gefitinib 250 mg Film-Coated Tablets | Pharmaceutical particulars - Shelf life | Shelf life
3 years
6.4 |
Gefitinib 250 mg Film-Coated Tablets | Pharmaceutical particulars - Special precautions for storage | Special precautions for storage
This medicinal product does not require any special storage conditions.
6.5 |
Gefitinib 250 mg Film-Coated Tablets | Pharmaceutical particulars - Nature and contents of container | Nature and contents of container
oPA/Al/PVC-Al perforated or non-perforated blister.
Boxes containing 30 tablets or 30 x 1 tablet. Not all pack sizes may be marketed.
6.6 |
Gefitinib 250 mg Film-Coated Tablets | Pharmaceutical particulars - Special precautions for disposal and other handling | Special precautions for disposal and other handling
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
7. |
Gefitinib 250 mg Film-Coated Tablets | Marketing authorisation holder | Genus Pharmaceuticals Ltd. (trading as 'STADA'),
Linthwaite, Huddersfield, HD7 5QH, UK
8. Marketing authorisation number(s)
PL 06831/0314
9. |
Gefitinib 250 mg Film-Coated Tablets | Date of first authorisation/renewal of the authorisation | 10/08/2018
10. |
Gefitinib 250 mg Film-Coated Tablets | Date of revision of the text | 22/02/2023 |
Gefitinib Glenmark 250 mg film-coated tablets | Name of the medicinal product | Gefitinib Glenmark 250 mg film-coated tablets
2. |
Gefitinib Glenmark 250 mg film-coated tablets | Qualitative and quantitative composition | Each film-coated tablet contains 250 mg of gefitinib.
Excipient with known effect:
Each film-coated tablet contains 161 mg of lactose (as monohydrate)
Each tablet contains 0.1 mg sodium
For the full list of excipients, see section 6.1.
3. |
Gefitinib Glenmark 250 mg film-coated tablets | Pharmaceutical form | Film-coated tablet (tablet).
The film-coated tablets are brown, round and biconvex, marked with “250” on one side and plain on the other.
The film-coated tablets have a diameter of approx. 11.1 mm and a thickness of approx. 5.6 mm.
4. |
Gefitinib Glenmark 250 mg film-coated tablets | Clinical particulars - Therapeutic indications | Therapeutic indications
Gefitinib Glenmark is indicated as monotherapy for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of EGFR-TK (see section 4.4).
4.2 |
Gefitinib Glenmark 250 mg film-coated tablets | Clinical particulars - Posology and method of administration | Posology and method of administration
Treatment with Gefitinib Glenmark should be initiated and supervised by a physician experienced in the use of anti-cancer therapies.
Posology
The recommended posology of Gefitinib Glenmark is one 250 mg tablet once a day. If a dose is missed, it should be taken as soon as the patient remembers. If it is less than 12 hours to the next dose, the patient should not take the missed dose. Patients should not take a double dose (two doses at the same time) to make up for a forgotten dose.
Paediatric population
The safety and efficacy of Gefitinib Glenmark in children and adolescents aged less than 18 years has not been established. There is no relevant use of gefitinib in the paediatric population in the indication of NSCLC.
Hepatic impairment
Patients with moderate to severe hepatic impairment (Child-Pugh B or C) due to cirrhosis have increased plasma concentrations of gefitinib. These patients should be closely monitored for adverse events. Plasma concentrations were not increased in patients with elevated aspartate transaminase (AST), alkaline phosphatase or bilirubin due to liver metastases (see section 5.2).
Renal impairment
No dose adjustment is required in patients with impaired renal function at creatinine clearance > 20 ml/min. Only limited data are available in patients with creatinine clearance ≤ 20 ml/min and caution is advised in these patients (see section 5.2).
Elderly
No dose adjustment is required on the basis of patient age (see section 5.2).
CYP2D6 poor metabolisers
No specific dose adjustment is recommended in patients with known CYP2D6 poor metaboliser genotype, but these patients should be closely monitored for adverse events (see section 5.2).
Dose adjustment due to toxicity
Patients with poorly tolerated diarrhoea or skin adverse reactions may be successfully managed by providing a brief (up to 14 days) therapy interruption followed by reinstatement of the 250 mg dose (see section 4.8). For patients unable to tolerate treatment after a therapy interruption, gefitinib should be discontinued and an alternative treatment should be considered.
Method of administration
The tablet may be taken orally with or without food, at about the same time each day. The tablet can be swallowed whole with some water or if dosing of whole tablets is not possible, tablets may be administered as a dispersion in water (non-carbonated). No other liquids should be used. Without crushing it, the tablet should be dropped in half a glass of drinking water. The glass should be swirled occasionally, until the tablet is dispersed (this may take up to 20 minutes). The dispersion should be drunk immediately after dispersion is complete (i.e. within 60 minutes). The glass should be rinsed with half a glass of water, which should also be drunk. The dispersion can also be administered through a naso-gastric or gastrostomy tube.
4.3 |
Gefitinib Glenmark 250 mg film-coated tablets | Clinical particulars - Contraindications | Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Breast-feeding (see section 4.6).
4.4 |
Gefitinib Glenmark 250 mg film-coated tablets | Clinical particulars - Special warnings and precautions for use | Special warnings and precautions for use
When considering the use of Gefitinib Glenmark as a treatment for locally advanced or metastatic NSCLC, it is important that EGFR mutation assessment of the tumour tissue is attempted for all patients. If a tumour sample is not evaluable, then circulating tumour DNA (ctDNA) obtained from a blood (plasma) sample may be used.
Only robust, reliable and sensitive test(s) with demonstrated utility for the determination of EGFR mutation status of tumours or ctDNA should be used to avoid false negative or false positive determinations (see section 5.1).
Interstitial lung disease (ILD)
Interstitial lung disease (ILD), which may be acute in onset, has been observed in 1.3 % of patients receiving gefitinib, and some cases have been fatal (see section 4.8). If patients experience worsening of respiratory symptoms such as dyspnoea, cough and fever, Gefitinib Glenmark should be interrupted and the patient should be promptly investigated. If ILD is confirmed, Gefitinib Glenmark should be discontinued and the patient treated appropriately.
In a Japanese pharmacoepidemiological case control study in 3,159 patients with NSCLC receiving gefitinib or chemotherapy who were followed up for 12 weeks, the following risk factors for developing ILD (irrespective of whether the patient received gefitinib or chemotherapy) were identified: smoking, poor performance status (PS≥ 2), CT scan evidence of reduced normal lung (≤ 50%), recent diagnosis of NSCLC (< 6 months), pre-existing ILD, older age (≥ 55 years old) and concurrent cardiac disease. An increased risk of ILD on gefitinib relative to chemotherapy was seen predominantly during the first 4 weeks of treatment (adjusted OR 3.8; 95% CI 1.9 to 7.7); thereafter the relative risk was lower (adjusted OR 2.5; 95% CI 1.1 to 5.8). Risk of mortality among patients who developed ILD on gefitinib or chemotherapy was higher in patients with the following risk factors: smoking, CT scan evidence of reduced normal lung (≤ 50%), pre-existing ILD, older age (≥ 65 years old), and extensive areas adherent to pleura (≥ 50%).
Hepatotoxicity and liver impairment
Liver function test abnormalities (including increases in alanine aminotransferase, aspartate aminotransferase, bilirubin) have been observed, uncommonly presenting as hepatitis (see section 4.8). There have been isolated reports of hepatic failure which in some cases led to fatal outcomes.
Therefore, periodic liver function testing is recommended. Gefitinib should be used cautiously in the presence of mild to moderate changes in liver function. Discontinuation should be considered if changes are severe.
Impaired liver function due to cirrhosis has been shown to lead to increased plasma concentrations of gefitinib (see section 5.2).
Interactions with other medicinal products
CYP3A4 inducers may increase metabolism of gefitinib and decrease gefitinib plasma concentrations. Therefore, concomitant administration of CYP3A4 inducers (e.g. phenytoin, carbamazepine, rifampicin, barbiturates or herbal preparations containing St John's wort/Hypericum perforatum) may reduce efficacy of the treatment and should be avoided (see section 4.5).
In individual patients with CYP2D6 poor metaboliser genotype, treatment with a potent CYP3A4 inhibitor might lead to increased plasma levels of gefitinib. At initiation of treatment with a CYP3A4 inhibitor, patients should be closely monitored for gefitinib adverse reactions (see section 4.5).
International normalised ratio (INR) elevations and/or bleeding events have been reported in some patients taking warfarin together with gefitinib (see section 4.5). Patients taking warfarin and gefitinib concomitantly should be monitored regularly for changes in prothrombin time (PT) or INR.
Medicinal products that cause significant sustained elevation in gastric pH, such as proton-pump inhibitors and h2-antagonists may reduce bioavailability and plasma concentrations of gefitinib and, therefore, may reduce efficacy. Antacids if taken regularly close in time to administration of gefitinib may have a similar effect (see sections 4.5 and 5.2).
Data from phase II clinical trials, where gefitinib and vinorelbine have been used concomitantly, indicate that gefitinib may exacerbate the neutropenic effect of vinorelbine.
Lactose
Gefitinib Glenmark contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactose deficiency or glucose-galactose malabsorption should not take this medicinal product.
Sodium
Each Gefitinib Glenmark tablet contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially 'sodium-free'.
Further precautions for use
Patients should be advised to seek medical advice immediately if they experience severe or persistent diarrhoea, nausea, vomiting or anorexia as these may indirectly lead to dehydration. These symptoms should be managed as clinically indicated (see section 4.8).
Patients presenting with signs and symptoms suggestive of keratitis such as acute or worsening: eye inflammation, lacrimation, light sensitivity, blurred vision, eye pain and/or red eye should be referred promptly to an ophthalmology specialist.
If a diagnosis of ulcerative keratitis is confirmed, treatment with gefitinib should be interrupted, and if symptoms do not resolve, or if symptoms recur on reintroduction of gefitinib, permanent discontinuation should be considered.
In a phase I/II trial studying the use of gefitinib and radiation in paediatric patients, with newly diagnosed brain stem glioma or incompletely resected supratentorial malignant glioma, 4 cases (1 fatal) of Central Nervous System (CNS) haemorrhages were reported from 45 patients enrolled. A further case of CNS haemorrhage has been reported in a child with an ependymoma from a trial with gefitinib alone. An increased risk of cerebral haemorrhage in adult patients with NSCLC receiving gefitinib has not been established.
Gastrointestinal perforation has been reported in patients taking gefitinib. In most cases this is associated with other known risk factors, including concomitant medications such as steroids or NSAIDS, underlying history of GI ulceration, age, smoking or bowel metastases at sites of perforation.
4.5 |
Gefitinib Glenmark 250 mg film-coated tablets | Clinical particulars - Interaction with other medicinal products and other forms of interaction | Interaction with other medicinal products and other forms of interaction
The metabolism of gefitinib is via the cytochrome P450 isoenzyme CYP3A4 (predominantly) and via CYP2D6.
Active substances that may increase gefitinib plasma concentrations
In vitro studies have shown that gefitinib is a substrate of p-glycoprotein (Pgp). Available data do not suggest any clinical consequences to this in vitro finding.
Substances that inhibit CYP3A4 may decrease the clearance of gefitinib. Concomitant administration with potent inhibitors of CYP3A4 activity (e.g. ketoconazole, posaconazole, voriconazole, protease inhibitors, clarithromycin, telithromycin) may increase gefitinib plasma concentrations. The increase may be clinically relevant since adverse reactions are related to dose and exposure. The increase might be higher in individual patients with CYP2D6 poor metaboliser genotype. Pre-treatment with itraconazole (a potent CYP3A4 inhibitor) resulted in an 80% increase in the mean AUC of gefitinib in healthy volunteers. In situations of concomitant treatment with potent inhibitors of CYP3A4 the patient should be closely monitored for gefitinib adverse reactions.
There are no data on concomitant treatment with an inhibitor of CYP2D6 but potent inhibitors of this enzyme might cause increased plasma concentrations of gefitinib in CYP2D6 extensive metabolisers by about 2-fold (see section 5.2). If concomitant treatment with a potent CYP2D6 inhibitor is initiated, the patient should be closely monitored for adverse reactions.
Active substances that may reduce gefitinib plasma concentrations
Substances that are inducers of CYP3A4 activity may increase metabolism and decrease gefitinib plasma concentrations and thereby reduce the efficacy of gefitinib. Concomitant medicinal products that induce CYP3A4 (e.g. phenytoin, carbamazepine, rifampicin, barbiturates or St John's wort, Hypericum perforatum) should be avoided. Pre-treatment with rifampicin (a potent CYP3A4 inducer) in healthy volunteers reduced mean gefitinib AUC by 83% (see section 4.4).
Substances that cause significant sustained elevation in gastric pH may reduce gefitinib plasma concentrations and thereby reduce the efficacy of gefitinib. High doses of short-acting antacids may have a similar effect if taken regularly close in time to administration of gefitinib. Concomitant administration of gefitinib with ranitidine at a dose that caused sustained elevations in gastric pH ≥5 resulted in a reduced mean gefitinib AUC by 47% in healthy volunteers (see section 4.4 and 5.2).
Active substances that may have their plasma concentrations altered by gefitinib
In vitro studies have shown that gefitinib has limited potential to inhibit CYP2D6. In a clinical trial in patients, gefitinib was co-administered with metoprolol (a CYP2D6 substrate). This resulted in a 35% increase in exposure to metoprolol. Such an increase might potentially be relevant for CYP2D6 substrates with narrow therapeutic index. When the use of CYP2D6 substrates are considered in combination with gefitinib, a dose modification of the CYP2D6 substrate should be considered especially for products with a narrow therapeutic window.
Gefitinib inhibits the transporter protein BCRP in vitro, but the clinical relevance of this finding is unknown.
Other potential interactions
INR elevations and/or bleeding events have been reported in some patients concomitantly taking warfarin (see section 4.4).
4.6 |
Gefitinib Glenmark 250 mg film-coated tablets | Clinical particulars - Fertility, pregnancy and lactation | Fertility, pregnancy and lactation
Women of childbearing potential
Women of childbearing potential must be advised not to get pregnant during therapy.
Pregnancy
There are no data from the use of gefitinib in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown. Gefitinib Glenmark should not be used during pregnancy unless clearly necessary.
Breast-feeding
It is not known whether gefitinib is secreted in human milk. Gefitinib and metabolites of gefitinib accumulated in milk of lactating rats (see section 5.3). Gefitinib is contraindicated during breast-feeding and therefore breast-feeding must be discontinued while receiving gefitinib therapy (see section 4.3).
4.7 |
Gefitinib Glenmark 250 mg film-coated tablets | Clinical particulars - Effects on ability to drive and use machines | Effects on ability to drive and use machines
During treatment with gefitinib, asthenia has been reported. Therefore, patients who experience this symptom should be cautious when driving or using machines.
4.8 |
Gefitinib Glenmark 250 mg film-coated tablets | Clinical particulars - Undesirable effects | Undesirable effects
Summary of the safety profile
In the pooled dataset from the ISEL, INTEREST and IPASS phase III clinical trials (2462 gefitinib-treated patients), the most frequently reported adverse drug reactions (ADRs), occurring in more than 20% of the patients, are diarrhoea and skin reactions (including rash, acne, dry skin and pruritus). ADRs usually occur within the first month of therapy and are generally reversible. Approximately 8% of patients had a severe ADR (common toxicity criteria, (CTC) grade 3 or 4).
Approximately 3% of patients stopped therapy due to an ADR.
Interstitial lung disease (ILD) has occurred in 1.3% of patients, often severe (CTC grade 3-4). Cases with fatal outcomes have been reported.
Tabulated list of adverse reactions
The safety profile presented in Table 1 is based on the gefitinib clinical development programme and postmarketed experience. Adverse reactions have been assigned to the frequency categories in Table 1 where possible based on the incidence of comparable adverse event reports in a pooled dataset from the ISEL, INTEREST and IPASS phase III clinical trials (2462 gefitinib-treated patients).
Frequencies of occurrence of undesirable effects are defined as: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000), not known (cannot be estimated from the available data).
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
Table 1 Adverse reactions
Adverse reactions by system organ class and frequency
Metabolism and nutrition disorders
Very common
Anorexia mild or moderate (CTC grade 1 or 2).
Eye disorders
Common
Conjunctivitis, blepharitis, and dry eye*, mainly mild (CTC grade 1).
Uncommon
Corneal erosion, reversible and sometimes in association with aberrant eyelash growth.
Keratitis (0.12%)
Vascular disorders
Common
Haemorrhage, such as epistaxis and haematuria.
Respiratory, thoracic and mediastinal disorders
Common
Interstitial lung disease (1.3%), often severe (CTC grade 3-4). Cases with fatal outcomes have been reported.
Gastrointestinal disorders
Very common
Diarrhoea, mainly mild or moderate (CTC grade 1 or 2).
Vomiting, mainly mild or moderate (CTC grade 1 or 2).
Nausea, mainly mild (CTC grade 1).
Stomatitis, predominantly mild in nature (CTC grade 1).
Common
Dehydration, secondary to diarrhoea, nausea, vomiting or anorexia.
Dry mouth*, predominantly mild (CTC grade 1).
Uncommon
Pancreatitis.
Gastrointestinal perforation.
Hepatobiliary disorders
Very common
Elevations in alanine aminotransferase, mainly mild to moderate.
Common
Elevations in aspartate aminotransferase, mainly mild to moderate.
Elevations in total bilirubin, mainly mild to moderate.
Uncommon
Hepatitis**
Skin and subcutaneous tissue disorders
Very common
Skin reactions, mainly a mild or moderate (CTC grade 1 or 2) pustular rash, sometimes itchy with dry skin, including skin fissures, on an erythematous base.
Common
Nail disorder
Alopecia
Allergic reactions (1.1%), including angioedema and urticaria
Uncommon
Palmar-plantar erythrodysaesthesia syndrome
Rare
Bullous conditions including Toxic epidermal necrolysis, Stevens Johnson syndrome and erythema multiforme
Cutaneous vasculitis
Renal and urinary disorders
Common
Asymptomatic laboratory elevations in blood creatinine
Proteinuria
Cystitis
Rare
Haemorrhagic cystitis
General disorders and administration site conditions
Very common
Asthenia, predominantly mild (CTC grade 1).
Common
Pyrexia
The frequency of adverse drug reactions relating to abnormal laboratory values is based on patients with a change from baseline of 2 or more CTC grades in the relevant laboratory parameters.
* This adverse reaction can occur in association with other dry conditions (mainly skin reactions) seen with gefitinib.
** This includes isolated reports of hepatic failure which in some cases led to fatal outcomes
Interstitial lung disease (ILD)
In the INTEREST trial, the incidence of ILD type events was 1.4% (10) patients in the gefitinib group versus 1.1% (8) patients in the docetaxel group. One ILD-type event was fatal, and this occurred in a patient receiving gefitinib.
In the ISEL trial, the incidence of ILD-type events in the overall population was approximately 1% in both treatment arms. The majority of ILD-type events reported was from patients of Asian ethnicity and the ILD incidence among patients of Asian ethnicity receiving gefitinib therapy and placebo was approximately 3% and 4% respectively. One ILD-type event was fatal, and this occurred in a patient receiving placebo.
In a post-marketing surveillance study in Japan (3350 patients) the reported rate of ILD-type events in patients receiving gefitinib was 5.8%. The proportion of ILD-type events with a fatal outcome was 38.6%.
In a phase III open-label clinical trial (IPASS) in 1217 patients comparing gefitinib to carboplatin/paclitaxel doublet chemotherapy as first-line treatment in selected patients with advanced NSCLC in Asia, the incidence of ILD-type events was 2.6% on the gefitinib treatment arm versus 1.4% on the carboplatin/paclitaxel treatment arm.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
4.9 |
Gefitinib Glenmark 250 mg film-coated tablets | Clinical particulars - Overdose | Overdose
There is no specific treatment in the event of overdose of gefitinib. However, in phase I clinical trials, a limited number of patients were treated with daily doses of up to 1000 mg. An increase of frequency and severity of some adverse reactions was observed, mainly diarrhoea and skin rash. Adverse reactions associated with overdose should be treated symptomatically; in particular severe diarrhoea should be managed as clinically indicated. In one study a limited number of patients were treated weekly with doses from 1500 mg to 3500 mg. In this study gefitinib exposure did not increase with increasing dose, adverse events were mostly mild to moderate in severity, and were consistent with the known safety profile of gefitinib.
5. Pharmacological properties
5.1 |
Gefitinib Glenmark 250 mg film-coated tablets | Pharmacodynamic properties - Pharmacodynamic properties | Pharmacokinetic properties
Absorption
Following oral administration of gefitinib, absorption is moderately slow and peak plasma concentrations of gefitinib typically occur at 3 to 7 hours after administration. Mean absolute bioavailability is 59% in cancer patients. Exposure to gefitinib is not significantly altered by food. In a trial in healthy volunteers where gastric pH was maintained above pH 5, gefitinib exposure was reduced by 47%, likely due to impaired solubility of gefitinib in the stomach (see sections 4.4 and 4.5).
Distribution
Gefitinib has a mean steady-state volume of distribution of 1400 l indicating extensive distribution into tissue. Plasma protein binding is approximately 90%. Gefitinib binds to serum albumin and alpha 1-acid glycoprotein. In vitro data indicate that gefitinib is a substrate for the membrane transport protein Pg-p.
Biotransformation
In vitro data indicate that CYP3A4 and CYP2D6 are the major P450 isozyme involved in the oxidative metabolism of gefitinib.
In vitro studies have shown that gefitinib has limited potential to inhibit CYP2D6. Gefitinib shows no enzyme induction effects in animal studies and no significant inhibition (in vitro) of any other cytochrome P450 enzyme.
Gefitinib is extensively metabolised in humans. Five metabolites have been fully identified in excreta and 8 metabolites in plasma. The major metabolite identified was O-desmethyl gefitinib, which is 14-fold less potent than gefitinib at inhibiting EGFR stimulated cell growth and has no inhibitory effect on tumour cell growth in mice. It is therefore considered unlikely that it contributes to the clinical activity of gefitinib.
The formation of O-desmethyl gefitinib has been shown, in vitro, to be via CYP2D6. The role of CYP2D6 in the metabolic clearance of gefitinib has been evaluated in a clinical trial in healthy volunteers genotyped for CYP2D6 status. In poor metabolisers no measurable levels of O-desmethyl gefitinib were produced. The levels of exposure to gefitinib achieved in both the extensive and the poor metaboliser groups were wide and overlapping but the mean exposure to gefitinib was 2-fold higher in the poor metaboliser group. The higher average exposures that could be achieved by individuals with no active CYP2D6 may be clinically relevant since adverse effects are related to dose and exposure.
Elimination
Gefitinib is excreted mainly as metabolites via the faeces, with renal elimination of gefitinib and metabolites accounting for less than 4% of the administered dose.
Gefitinib total plasma clearance is approximately 500 ml/min and the mean terminal half-life is 41 hours in cancer patients. Administration of gefitinib once daily results in 2- to 8-fold accumulation, with steady-state exposures achieved after 7 to 10 doses. At steady-state, circulating plasma concentrations are typically maintained within a 2- to 3-fold range over the 24-hour dosing interval.
Special populations
From analyses of population pharmacokinetic data in cancer patients, no relationships were identified between predicted steady-state trough concentration and patient age, body weight, gender, ethnicity or creatinine clearance (above 20 ml/min).
Hepatic impairment
In a phase I open-label study of single dose gefitinib 250 mg in patients with mild, moderate or severe hepatic impairment due to cirrhosis (according to Child-Pugh classification), there was an increase in exposure in all groups compared with healthy controls. An average 3.1-fold increase in exposure to gefitinib in patients with moderate and severe hepatic impairment was observed. None of the patients had cancer, all had cirrhosis and some had hepatitis. This increase in exposure may be of clinical relevance since adverse experiences are related to dose and exposure to gefitinib.
Gefitinib has been evaluated in a clinical trial conducted in 41 patients with solid tumours and normal hepatic function, or moderate or severe hepatic impairment (classified according to baseline Common Toxicity Criteria grades for AST, alkaline phosphatase and bilirubin) due to liver metastases. It was shown that following daily administration of 250 mg gefitinib, time to steady-state, total plasma clearance (CmaxSS) and steady-state exposure (AUC24SS) were similar for the groups with normal and moderately impaired hepatic function. Data from 4 patients with severe hepatic impairment due to liver metastases suggested that steady-state exposures in these patients are also similar to those in patients with normal hepatic function.
5.3 |
Gefitinib Glenmark 250 mg film-coated tablets | Pharmacodynamic properties - Pharmacokinetic properties | Preclinical safety data
Adverse reactions not observed in clinical studies, but seen in animals at exposure levels similar to the clinical exposure levels and with possible relevance to clinical use were as follows:
- Corneal epithelia atrophy and corneal translucencies
- Renal papillary necrosis
- Hepatocellular necrosis and eosinophilic sinusoidal macrophage infiltration
Data from non-clinical (in vitro) studies indicate that gefitinib has the potential to inhibit the cardiac action potential repolarization process (e.g. QT interval). Clinical experience has not shown a causal association between QT prolongation and gefitinib.
A reduction in female fertility was observed in the rat at a dose of 20 mg/kg/day.
Published studies have shown that genetically modified mice, lacking expression of EGFR, exhibit developmental defects, related to epithelial immaturity in a variety of organs including the skin, gastrointestinal tract and lung. When gefitinib was administered to rats during organogenesis, there were no effects on embryofoetal development at the highest dose (30 mg/kg/day). However, in the rabbit, there were reduced foetal weights at 20 mg/kg/day and above. There were no compound-induced malformations in either species. When administered to the rat throughout gestation and parturition, there was a reduction in pup survival at a dose of 20 mg/kg/day.
Following oral administration of C-14 labelled gefitinib to lactating rats 14 days post-partum, concentrations of radioactivity in milk were 11-19 fold higher than in blood.
Gefitinib showed no genotoxic potential.
A 2-year carcinogenicity study in rats resulted in a small but statistically significant increased incidence of hepatocellular adenomas in both male and female rats and mesenteric lymph node haemangiosarcomas in female rats at the highest dose (10 mg/kg/day) only. The hepatocellular adenomas were also seen in a 2-year carcinogenicity study in mice, which demonstrated a small increased incidence of this finding in male mice at the mid dose, and in both male and female mice at the highest dose. The effects reached statistical significance for the female mice, but not for the males. At no-effect levels in both mice and rats there was no margin in clinical exposure. The clinical relevance of these findings is unknown.
The results of an in vitro phototoxicity study demonstrated that gefitinib may have phototoxicity potential.
6. |
Gefitinib Glenmark 250 mg film-coated tablets | Pharmaceutical particulars - List of excipients | List of excipients
Tablet core
Lactose monohydrate
Microcrystalline cellulose
Crospovidone
Povidone
Sodium laurilsulfate
Magnesium stearate
Tablet coating
Polyvinyl alcohol
Macrogol
Talc
Titanium dioxide (E171)
Red iron oxide (E172)
Yellow iron oxide (E172)
6.2 |
Gefitinib Glenmark 250 mg film-coated tablets | Pharmaceutical particulars - Incompatibilities | Incompatibilities
Not applicable.
6.3 |
Gefitinib Glenmark 250 mg film-coated tablets | Pharmaceutical particulars - Shelf life | Shelf life
24 months.
6.4 |
Gefitinib Glenmark 250 mg film-coated tablets | Pharmaceutical particulars - Special precautions for storage | Special precautions for storage
Do not store above 30 °C
6.5 |
Gefitinib Glenmark 250 mg film-coated tablets | Pharmaceutical particulars - Nature and contents of container | Nature and contents of container
PVC/PVDC-Aluminium perforated blister containing 10 tablets or PVC/PVDC-Aluminium non-perforated blister containing 10 tablets.
Additionally, the blisters may be packed into aluminium pouches.
Pack size of 30 film-coated tablets. Not all pack sizes may be marketed.
6.6 |
Gefitinib Glenmark 250 mg film-coated tablets | Pharmaceutical particulars - Special precautions for disposal and other handling | Special precautions for disposal and other handling
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
7. |
Gefitinib Glenmark 250 mg film-coated tablets | Marketing authorisation holder | Glenmark Pharmaceuticals Europe Limited
Laxmi House, 2B Draycott Avenue
Kenton, Middlesex
HA3 0BU
United Kingdom
8. Marketing authorisation number(s)
PL 25258/0277
9. |
Gefitinib Glenmark 250 mg film-coated tablets | Date of first authorisation/renewal of the authorisation | 05/09/2018
10. |
Gefitinib Glenmark 250 mg film-coated tablets | Date of revision of the text | 13/12/2021 |
Glycerin Suppositories BP 1g Infants' Size | Name of the medicinal product | Glycerin Suppositories BP 1g Infants' Size
2. |
Glycerin Suppositories BP 1g Infants' Size | Qualitative and quantitative composition | Glycerol BP 70% w/w
3. |
Glycerin Suppositories BP 1g Infants' Size | Pharmaceutical form | Suppositories.
4. |
Glycerin Suppositories BP 1g Infants' Size | Clinical particulars - Therapeutic indications | Therapeutic indications
For the relief of occasional constipation.
4.2 |
Glycerin Suppositories BP 1g Infants' Size | Clinical particulars - Posology and method of administration | Posology and method of administration
Route of administration:
Rectal.
Dose:
One suppository.
Dosage schedule:
As required.
The suppository should be dipped in water before insertion.The suppositories are defined as infants' size, therefore there is no adults' or children's use recommendation.
4.3 |
Glycerin Suppositories BP 1g Infants' Size | Clinical particulars - Contraindications | Contraindications
Contraindicated in patients with known hypersensitivity to glycerol.
4.4 |
Glycerin Suppositories BP 1g Infants' Size | Clinical particulars - Special warnings and precautions for use | Special warnings and precautions for use
Keep all medicines away from children.Not to be swallowed. Suppositories must not be taken by mouth. Consult your doctor before use.
4.5 |
Glycerin Suppositories BP 1g Infants' Size | Clinical particulars - Interaction with other medicinal products and other forms of interaction | Interaction with other medicinal products and other forms of interaction
None known.
4.6. |
Glycerin Suppositories BP 1g Infants' Size | Clinical particulars - Fertility, pregnancy and lactation | Fertility, pregnancy and lactation
Not applicable.
4.7 |
Glycerin Suppositories BP 1g Infants' Size | Clinical particulars - Effects on ability to drive and use machines | Effects on ability to drive and use machines
None.
4.8 |
Glycerin Suppositories BP 1g Infants' Size | Clinical particulars - Undesirable effects | Undesirable effects
Gastrointestinal Disorders: May cause irritation and occasionally abdominal cramps.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.
4.9 |
Glycerin Suppositories BP 1g Infants' Size | Clinical particulars - Overdose | Overdose
Glycerol has a mildly laxative action, however, if the product is accidentally swallowed it is unlikely to cause such effects and it is unlikely that active measures will be required. Accidental ingestion of a large number of suppositories may cause headache, nausea and vomiting; less frequently diarrhoea, thirst, dizziness, mental confusion and cardiac arrhythmias can occur.
5. Pharmacological properties
5.1 |
Glycerin Suppositories BP 1g Infants' Size | Pharmacodynamic properties - Pharmacodynamic properties | Pharmacokinetic properties
No information available.
5.3 |
Glycerin Suppositories BP 1g Infants' Size | Pharmacodynamic properties - Pharmacokinetic properties | Preclinical safety data
None.
6. |
Glycerin Suppositories BP 1g Infants' Size | Pharmaceutical particulars - List of excipients | List of excipients
Gelatin Purified Water
6.2 |
Glycerin Suppositories BP 1g Infants' Size | Pharmaceutical particulars - Incompatibilities | Incompatibilities
None known.
6.3 |
Glycerin Suppositories BP 1g Infants' Size | Pharmaceutical particulars - Shelf life | Shelf life
18 months unopened.
6.4 |
Glycerin Suppositories BP 1g Infants' Size | Pharmaceutical particulars - Special precautions for storage | Special precautions for storage
Store below 25°C in a dry place.
6.5 |
Glycerin Suppositories BP 1g Infants' Size | Pharmaceutical particulars - Nature and contents of container | Nature and contents of container
12's: Sealed, PVC/PE laminate inside a cardboard carton.
6.6 |
Glycerin Suppositories BP 1g Infants' Size | Pharmaceutical particulars - Special precautions for disposal and other handling | Special precautions for disposal and other handling
None.
7. |
Glycerin Suppositories BP 1g Infants' Size | Marketing authorisation holder | Thornton & Ross Ltd.Linthwaite LaboratoriesHuddersfieldHD7 5QH.
8. Marketing authorisation number(s)
PL 00240/6100R
9. |
Glycerin Suppositories BP 1g Infants' Size | Date of first authorisation/renewal of the authorisation | 1st August 1986 / 22nd April 1993, 9th September 1998
10. |
Glycerin Suppositories BP 1g Infants' Size | Date of revision of the text | 26/11/2014 |
Glycerin Suppositories BP 2g Children's Size | Name of the medicinal product | Glycerin Suppositories BP 2g Children's Size.
2. |
Glycerin Suppositories BP 2g Children's Size | Qualitative and quantitative composition | Glycerol BP 70% w/w.
3. |
Glycerin Suppositories BP 2g Children's Size | Pharmaceutical form | Suppositories.
4. |
Glycerin Suppositories BP 2g Children's Size | Clinical particulars - Therapeutic indications | Therapeutic indications
For the relief of occasional constipation.
4.2 |
Glycerin Suppositories BP 2g Children's Size | Clinical particulars - Posology and method of administration | Posology and method of administration
Route of administration:
Rectal.
Dose:
One suppository.
Dosage Schedule:
As required.
The suppository should be dipped in water before insertion.The suppositories are defined as children's size, therefore there is no infants' or adults' recommendation
4.3 |
Glycerin Suppositories BP 2g Children's Size | Clinical particulars - Contraindications | Contraindications
Contraindicated in patients with known hypersensitivity to glycerol.Children's Suppositories are not suitable for use by infants (under 1 year).
4.4 |
Glycerin Suppositories BP 2g Children's Size | Clinical particulars - Special warnings and precautions for use | Special warnings and precautions for use
Keep all medicines away from children.Not to be swallowed.Suppositories must not be taken by mouth.
4.5 |
Glycerin Suppositories BP 2g Children's Size | Clinical particulars - Interaction with other medicinal products and other forms of interaction | Interaction with other medicinal products and other forms of interaction
None known.
4.6. |
Glycerin Suppositories BP 2g Children's Size | Clinical particulars - Fertility, pregnancy and lactation | Fertility, pregnancy and lactation
Not applicable.
4.7 |
Glycerin Suppositories BP 2g Children's Size | Clinical particulars - Effects on ability to drive and use machines | Effects on ability to drive and use machines
None.
4.8 |
Glycerin Suppositories BP 2g Children's Size | Clinical particulars - Undesirable effects | Undesirable effects
Gastrointestinal Disorders: May cause irritation and occasionally abdominal cramps.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.
4.9 |
Glycerin Suppositories BP 2g Children's Size | Clinical particulars - Overdose | Overdose
Glycerol has a mildly laxative action, however, if the product is accidentally swallowed it is unlikely to cause such effects and it is unlikely that active measures will be required. Accidental ingestion of a large number of suppositories may cause headache, nausea and vomiting; less frequently diarrhoea, thirst; dizziness, mental confusion and cardiac arrhythniias can occur.
5. Pharmacological properties
5.1 |
Glycerin Suppositories BP 2g Children's Size | Pharmacodynamic properties - Pharmacodynamic properties | Pharmacokinetic properties
No information available.
5.3 |
Glycerin Suppositories BP 2g Children's Size | Pharmacodynamic properties - Pharmacokinetic properties | Preclinical safety data
None.
6. |
Glycerin Suppositories BP 2g Children's Size | Pharmaceutical particulars - List of excipients | List of excipients
Gelatin Purified Water
6.2 |
Glycerin Suppositories BP 2g Children's Size | Pharmaceutical particulars - Incompatibilities | Incompatibilities
None known.
6.3 |
Glycerin Suppositories BP 2g Children's Size | Pharmaceutical particulars - Shelf life | Shelf life
18 months unopened.
6.4 |
Glycerin Suppositories BP 2g Children's Size | Pharmaceutical particulars - Special precautions for storage | Special precautions for storage
Store below 25°C in a dry place.
6.5 |
Glycerin Suppositories BP 2g Children's Size | Pharmaceutical particulars - Nature and contents of container | Nature and contents of container
12's: Sealed, PVC/PE laminate inside a cardboard carton.
6.6 |
Glycerin Suppositories BP 2g Children's Size | Pharmaceutical particulars - Special precautions for disposal and other handling | Special precautions for disposal and other handling
None.
7. |
Glycerin Suppositories BP 2g Children's Size | Marketing authorisation holder | Thornton & Ross Ltd.Linthwaite LaboratoriesHuddersfieldHD7 5QH.
8. Marketing authorisation number(s)
PL: 00240/6101R
9. |
Glycerin Suppositories BP 2g Children's Size | Date of first authorisation/renewal of the authorisation | 1st August 1986 / 22nd April 1993, 25th November 1998
10. |
Glycerin Suppositories BP 2g Children's Size | Date of revision of the text | 26/11/2014 |
Glycerin Suppositories BP 4g Adult Size | Name of the medicinal product | Glycerin Suppositories BP 4g Adult Size Superdrug Glycerine Constipation Relief SuppositoriesBoots Constipation Relief SuppositoriesSainsburys Constipation Relief SuppositoriesTesco Constipation Relief Suppositories
2. |
Glycerin Suppositories BP 4g Adult Size | Qualitative and quantitative composition | Glycerol 70.0% w/w
3. |
Glycerin Suppositories BP 4g Adult Size | Pharmaceutical form | Suppository.
4. |
Glycerin Suppositories BP 4g Adult Size | Clinical particulars - Therapeutic indications | Therapeutic indications
For the relief of occasional constipation
4.2 |
Glycerin Suppositories BP 4g Adult Size | Clinical particulars - Posology and method of administration | Posology and method of administration
Rectal.
RECOMMENDED DOSES AND DOSAGE SCHEDULES
One suppository as required.The suppository should be dipped in water before insertion.The suppositories are defined as adult size, therefore there is no children's use recommendation.They are suitable for use by the elderly, dose and dosage schedule as above.
4.3 |
Glycerin Suppositories BP 4g Adult Size | Clinical particulars - Contraindications | Contraindications
Contra-indicated in patients with known hypersensitivity to glycerol. Adults suppositories are not suitable for use by children and infants.
4.4 |
Glycerin Suppositories BP 4g Adult Size | Clinical particulars - Special warnings and precautions for use | Special warnings and precautions for use
Keep all medicines away from children.Not to be swallowed.Suppositories must not be taken by mouth.
4.5 |
Glycerin Suppositories BP 4g Adult Size | Clinical particulars - Interaction with other medicinal products and other forms of interaction | Interaction with other medicinal products and other forms of interaction
None known.
4.6. |
Glycerin Suppositories BP 4g Adult Size | Clinical particulars - Fertility, pregnancy and lactation | Fertility, pregnancy and lactation
All medicines should be avoided if possible during pregnancy and lactation. Use only under a doctor's instruction in these conditions.
4.7 |
Glycerin Suppositories BP 4g Adult Size | Clinical particulars - Effects on ability to drive and use machines | Effects on ability to drive and use machines
None.
4.8 |
Glycerin Suppositories BP 4g Adult Size | Clinical particulars - Undesirable effects | Undesirable effects
Gastrointestinal Disorders: May cause irritation and occasionally abdominal cramps.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.
4.9 |
Glycerin Suppositories BP 4g Adult Size | Clinical particulars - Overdose | Overdose
Glycerol has a mildly laxative action, however, if the product is accidentally swallowed it is unlikely to cause such effects and it is unlikely that active measures will be needed. Accidental ingestion of a large number of suppositories may cause headache, nausea and vomiting less frequently diarrhoea, thirst, dizziness, mental confusion and cardiac arrhythmias can occur.
5. Pharmacological properties
5.1 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.